<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00644904</url>
  </required_header>
  <id_info>
    <org_study_id>REB05-147</org_study_id>
    <nct_id>NCT00644904</nct_id>
  </id_info>
  <brief_title>Safety Trial of High Dose Oral Vitamin D3 With Calcium in Multiple Sclerosis</brief_title>
  <acronym>VitD4MS</acronym>
  <official_title>A Phase I/II Dose-Escalation Trial of Vitamin D3 With Calcium Supplementation in Patients With Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Direct MS-Proactive Charity</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Multiple Sclerosis Society of Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vitamin D likely plays a role in the geography of Multiple Sclerosis (MS), and patients at
      risk and with MS have relatively low Vitamin D levels compared to their normal counterparts.

      This trial examines the safety of high dose oral Vitamin D3 titrated up to a maximum of
      40,000 IU per day over a 12 month period. Fifty patients matched for MS and non-MS
      characteristics will be divided into two groups: one group receiving the high dose Vitamin D
      regimen, and the other restricted to a maximum of 4000 IU per day. The hypothesis is that
      patients with MS can tolerate seemingly high doses of Vitamin D3 without adverse events
      and/or calcium-related abnormalities. It is also hypothesized that those receiving the higher
      doses will demonstrate improved relapse and disability status compared to controls, and that
      the treatment group will show improved markers of bone health and immune indicators of
      reduced inflammation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum calcium</measure>
    <time_frame>at each dose change</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum 25(OH)D</measure>
    <time_frame>at each dose change</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EDSS</measure>
    <time_frame>at screening vs. end of trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>N-telopeptide (bone marker)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALP/AST/ALT</measure>
    <time_frame>at each dose change</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine/urea</measure>
    <time_frame>at each dose change</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EKG</measure>
    <time_frame>at screening and end of trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal ultrasound</measure>
    <time_frame>at screening, mid-trial and end of trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine profile/MMP/lymphocyte response assay</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized relapse rate</measure>
    <time_frame>year prior to trial versus year of trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PTH</measure>
    <time_frame>at each dose change</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Starting dose of 4,000 IU per day of Vitamin D3 titrating up to a dose of 40,000 IU per day of Vitamin D3 by month six. In the second six-month part of the trial, patients titrate back down to 4,000 IU per day of Vitamin D3 and then discontinue it completely at the end of the 12 month trial period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients are allowed to supplement with up to 4,000 IU per day of Vitamin D3 if desired.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinically definite MS

          -  Age 18-55

          -  EDSS 0-6.5

        Exclusion Criteria:

          -  EDSS =&gt; 7.0

          -  Current Vitamin D3 use &gt;4000 IU/d

          -  Baseline (25(OH)D) level &lt;20 mmol/L (frank deficiency) and &gt;150 mmol/L

          -  Pregnancy or inability/unwillingness to use contraception

          -  History of cardiac arrhythmia

          -  History of renal disease and nephrolithiasis

          -  History of granulomatous disease or lymphoma

          -  Relapse activity or steroid use in the past 60 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jodie M Burton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Michael's Hospital, University of Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul W O'Connor, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Michael's Hospital, University of Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Kimball SM, Ursell MR, O'Connor P, Vieth R. Safety of vitamin D3 in adults with multiple sclerosis. Am J Clin Nutr. 2007 Sep;86(3):645-51.</citation>
    <PMID>17823429</PMID>
  </reference>
  <verification_date>March 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2008</study_first_submitted>
  <study_first_submitted_qc>March 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2008</study_first_posted>
  <last_update_submitted>March 27, 2008</last_update_submitted>
  <last_update_submitted_qc>March 27, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 28, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr. Paul O'Connor</name_title>
    <organization>St. Michael's Hospital, Division of Neurology, University of Toronto</organization>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

